Results of a study: median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group.
Home / Resource Library / Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia